Gilead, LEO Pharma partner to develop programs for inflammatory diseases
(Reuters) – Gilead Sciences said on Saturday that it entered into a partnership with Denmark’s LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will be eligible to receive up to $1.7 billion in payments which include an upfront payment of $250 million from Gilead. In return, Gilead will have …
Gilead, LEO Pharma partner to develop programs for inflammatory diseases Read More »










